Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil slips but stays near six-month highs on Saudi attacks
- BofA flags further downside risk for stocks, yields and dollar
| ADVAXIS (AMEX: ADXS) | Delayed: 0.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.60 | 52 Week High | $16.30 | |||
| Open | $0.60 | 52 Week Low | $5.21 | |||
| Day High | $0.60 | P/E | N/A | |||
| Day Low | $0.60 | EPS | $-4.10 | |||
| Volume | 41,033 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 145.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $145.27 | 52 Week High | $65.46 | |||
| Open | $145.27 | 52 Week Low | $47.97 | |||
| Day High | $145.27 | P/E | 98.82 | |||
| Day Low | $145.27 | EPS | $1.47 | |||
| Volume | 15,409 | |||||
